Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
There are limited treatment options available for patients with advanced pancreatic ductal
adenocarcinoma (PDAC). The purpose of this study is to determine the effectiveness and safety
of the drugs capecitabine and oxaliplatin in patients who have been diagnosed with advanced
and metastatic PDAC treated in the first and second lines.